Which peptides are FDA approved?

What the 2026 vote changed, and what it didn’t.

Many peptide medicines are FDA approved and sold by prescription. The July 2026 advisory vote approved none. It recommended six peptides for pharmacy compounding. No rule has changed yet; in October, HHS published a draft policy on how it will treat pharmacies that compound those six while it decides.

Updated November 3, 2026

Approved, recommended, research use

Three labels that get mixed up online. They mean very different things.

FDA approved: The FDA reviewed human trials and found it safe and effective for a specific use.; Who can sell it: Drug makers, through licensed pharmacies.; How someone gets it: Usually with a prescription.

Recommended for compounding: An FDA advisory committee voted that pharmacies may be allowed to compound it. Not an approval, and not in effect until the FDA acts.; Who can sell it: Licensed compounding pharmacies, and only if the FDA adds it to its list.; How someone gets it: A prescription for an individual patient, once that happens.

Research use only: Sold for laboratory study. Not approved for use in people.; Who can sell it: Research suppliers.; How someone gets it: For laboratory research, not for use in people.

Label	What it means	Who can sell it	How someone gets it
FDA approved	The FDA reviewed human trials and found it safe and effective for a specific use.	Drug makers, through licensed pharmacies.	Usually with a prescription.
Recommended for compounding	An FDA advisory committee voted that pharmacies may be allowed to compound it. Not an approval, and not in effect until the FDA acts.	Licensed compounding pharmacies, and only if the FDA adds it to its list.	A prescription for an individual patient, once that happens.
Research use only	Sold for laboratory study. Not approved for use in people.	Research suppliers.	For laboratory research, not for use in people.

What happened in 2026

April 2026Twelve peptides came off the FDA’s Category 2 list, its list of substances that may raise significant safety risks in pharmacy compounding. They left because their nominations were withdrawn. That did not approve them or put them on any other list.
July 23–24The FDA’s Pharmacy Compounding Advisory Committee voted on seven peptides. It recommended six for the list pharmacies may compound from, each by two or three votes. The seventh failed by one.
October 28HHS, the FDA’s parent department, published a draft policy: it does not intend to take enforcement action against licensed pharmacies and physicians that compound the six, under set conditions, until rules settle each one’s status. Public comments close in mid-November.
TodayNo rule has been proposed or finalized, and none of the six is an approved drug. Another committee meeting on further peptides is expected before the end of February 2027.

“Banned” and “approved” are both wrong

Both words went around online in 2026. Neither is accurate.

Not a ban. Category 2 was an FDA policy on pharmacy compounding, not a ban on the substances themselves. Leaving it was not an approval either.
Not an approval. A committee advises; the FDA and HHS decide, through formal rulemaking. The July votes were recommendations, and the October policy is a draft statement about enforcement.
Only pharmacies. Even a final rule would let licensed compounding pharmacies prepare these peptides on a prescription. It would not make them approved drugs or over-the-counter products.

Are research peptides legal?

Research peptides are sold for laboratory research, not for use in people. Most peptides are not listed as controlled substances under federal law.

The FDA judges a product by all of its marketing, not only its label. It looks at the labeling, advertising, statements and how a product is sold, so a “research use only” label does not settle the question on its own. Some states also regulate certain compounds more tightly than federal law does.

Questions people ask

Is a recommended peptide now available?

Not as an approved drug. HHS’s October draft policy covers licensed pharmacies and physicians compounding the six on a prescription, under set conditions. It is not binding, and it does not cover products sold for research.

When will the FDA decide?

No date is set. Adding a peptide to the compounding list takes a proposed rule, public comment and a final rule, and that can take into 2027 or longer.

Is this legal advice?

No. This page summarizes public information from the FDA as of November 3, 2026. Rules change, and they differ by state.

Wondering about safety? Are peptides safe? The short answer, and the evidence behind it.

Sources

Education only, not medical or legal advice. This page summarizes public information from the FDA and other public sources as of November 3, 2026. Nothing here is a recommendation to use any compound in humans or animals. Compounds sold for research are for laboratory research use only and are not for human or veterinary consumption.